Pembrolizumab: given beside what is tested

1,547 studies: usual care or a partner of the new treatment. Page 2 of 16. Open to participants first (520), then studies with results posted, then the rest; newest registration first within each.

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory TumorsRecruitingNCT07404332Phase 1 Report a problem
Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCCRecruitingNCT07403136Phase 2 Report a problem
Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair DeficiencyNot yet recruitingNCT07385846Phase 1 Report a problem
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney CancerRecruitingNCT07383441Phase 3 Report a problem
The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related ToxicitiesRecruitingNCT07381634Phase 2 Report a problem
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.RecruitingNCT07365319Phase 2/3 Report a problem
HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICCRecruitingNCT07364305Phase 2 Report a problem
A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract CancersNot yet recruitingNCT07351591Phase 2 Report a problem
Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT GlioblastomaNot yet recruitingNCT07347210Phase 2 Report a problem
Study to Identify Biomarkers of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy Prior to Definitive SurgeryRecruitingNCT07343596Not applicable Report a problem
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null PhenotypeRecruitingNCT07341867Phase 1 Report a problem
Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell CarcinomaNot yet recruitingNCT07335380Phase 1 Report a problem
A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT07327229Phase 1/2 Report a problem
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 AstrocytomaRecruitingNCT07301268Phase 2 Report a problem
Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer PatientsNot yet recruitingNCT07300475Phase 1 Report a problem
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid TumorsRecruitingNCT07287995Phase 1/2 Report a problem
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid TumorsRecruitingNCT07287917Phase 1/2 Report a problem
Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung CancerEnrolling by invitationNCT07285434Early Phase 1 Report a problem
Amping up With PemJAKRecruitingNCT07283822Phase 2 Report a problem
Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue SarcomaRecruitingNCT07283731Phase 2 Report a problem
Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver CancerNot yet recruitingNCT07282509Phase 1/2 Report a problem
An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.RecruitingNCT07282262Phase 2 Report a problem
125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant TumorsNot yet recruitingNCT07277777Phase 2 Report a problem
Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast CancerRecruitingNCT07276880Phase 2 Report a problem
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck CancerRecruitingNCT07276399Phase 3 Report a problem
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLCRecruitingNCT07264816Phase 2 Report a problem
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) TumorsRecruitingNCT07262619Phase 1/2 Report a problem
A Study of QLC5508 Combinations in Patients With Advanced Solid TumorsRecruitingNCT07256782Phase 1/2 Report a problem
A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PCRecruitingNCT07255664Phase 1/2 Report a problem
SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell CarcinomaRecruitingNCT07254585Phase 2 Report a problem
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)RecruitingNCT07252739Phase 2 Report a problem
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)RecruitingNCT07247110Phase 1 Report a problem
Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate CancerRecruitingNCT07244393Phase 1 Report a problem
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)RecruitingNCT07232602Phase 1/2 Report a problem
A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other TherapiesRecruitingNCT07231458Phase 1 Report a problem
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic CancerRecruitingNCT07227168Phase 1 Report a problem
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid MalignanciesRecruitingNCT07223047Phase 1/2 Report a problem
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)RecruitingNCT07221474Phase 2 Report a problem
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary TractRecruitingNCT07218380Phase 3 Report a problem
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4Enrolling by invitationNCT07218003Phase 1 Report a problem
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial CancerNot yet recruitingNCT07217496Phase 1 Report a problem
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RecruitingNCT07216703Phase 3 Report a problem
Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid TumorsRecruitingNCT07215637Phase 1 Report a problem
Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell CarcinomaRecruitingNCT07213934Phase 1/2 Report a problem
A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.RecruitingNCT07207395Phase 2 Report a problem
TLN-372 in Advanced KRAS Mutant Solid TumorsRecruitingNCT07204340Phase 1 Report a problem
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)RecruitingNCT07190248Phase 3 Report a problem
A Study of DS5361b in Participants With Advanced Solid TumorsRecruitingNCT07182591Phase 1 Report a problem
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast CancerNot yet recruitingNCT07178730Phase 3 Report a problem
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) PatientsRecruitingNCT07176312Phase 2 Report a problem
SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and AnxietyRecruitingNCT07174947Phase 2 Report a problem
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid TumorsRecruitingNCT07166601Phase 1 Report a problem
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract CancerNot yet recruitingNCT07159217Phase 2 Report a problem
ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid TumorsRecruitingNCT07158918Phase 1/2 Report a problem
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCCRecruitingNCT07157969Phase 2 Report a problem
Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract CancerNot yet recruitingNCT07151872Phase 2 Report a problem
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)RecruitingNCT07139990Phase 1 Report a problem
A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)RecruitingNCT07136545Phase 1/2 Report a problem
Study of GS-5319 Given Alone or in Combination in Adults With Solid TumorsRecruitingNCT07128303Phase 1 Report a problem
A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsRecruitingNCT07123415Phase 1 Report a problem
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLCRecruitingNCT07098988Phase 2 Report a problem
Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid TumorsRecruitingNCT07095868Phase 1/2 Report a problem
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid TumorsRecruitingNCT07094113Phase 1 Report a problem
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsRecruitingNCT07090499Phase 1 Report a problem
Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder CancersRecruitingNCT07087860Phase 2 Report a problem
Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal AdenocarcinomaRecruitingNCT07082439Phase 2 Report a problem
TIL-Driven De-escalated Chemotherapy in Stage I-II TNBCRecruitingNCT07074106Phase 2 Report a problem
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionRecruitingNCT07063745Phase 2/3 Report a problem
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial CancerRecruitingNCT07054567Phase 2 Report a problem
A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)Not yet recruitingNCT07054242Phase 2 Report a problem
Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II TrialNot yet recruitingNCT07050524Phase 2 Report a problem
Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1Not yet recruitingNCT07040436Phase 1/2 Report a problem
Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After SurgeryRecruitingNCT07037004Phase 2 Report a problem
Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCCRecruitingNCT07026474Phase 3 Report a problem
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.RecruitingNCT07021898Phase 1 Report a problem
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsRecruitingNCT07020221Phase 1/2 Report a problem
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung CancerRecruitingNCT07017829Phase 2 Report a problem
A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors.RecruitingNCT07016997Phase 1 Report a problem
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBCRecruitingNCT07016399Phase 2 Report a problem
ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and RadiationNot yet recruitingNCT07015853Phase 2 Report a problem
Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-ImmunotherapyRecruitingNCT07014202Phase 2 Report a problem
Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBCNot yet recruitingNCT07011823Phase 2 Report a problem
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyNot yet recruitingNCT07010393Phase 4 Report a problem
Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric AdenocarcinomaRecruitingNCT07000253Phase 2 Report a problem
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid MalignanciesRecruitingNCT06994806Phase 1 Report a problem
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid TumorsRecruitingNCT06983743Phase 1 Report a problem
A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract CancerRecruitingNCT06978114Phase 2 Report a problem
Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast CancerRecruitingNCT06976944Phase 2 Report a problem
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RecruitingNCT06966700Phase 3 Report a problem
Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid TumorsRecruitingNCT06963814Phase 1 Report a problem
A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal CancerRecruitingNCT06962787Phase 2 Report a problem
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid TumorsRecruitingNCT06960395Phase 1 Report a problem
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RecruitingNCT06952504Phase 3 Report a problem
Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung CancerNot yet recruitingNCT06951399Phase 2 Report a problem
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D MutationNot yet recruitingNCT06949761Phase 1/2 Report a problem
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell CarcinomaRecruitingNCT06947928Phase 2/3 Report a problem
Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaNot yet recruitingNCT06942767Phase 2 Report a problem
Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast CancerRecruitingNCT06942234Phase 1/2 Report a problem
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)RecruitingNCT06940440Phase 1 Report a problem
Viscum Album for TNBC on Adjuvant PembrolizumabRecruitingNCT06920810Phase 4 Report a problem

← Pembrolizumab